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Group I CD1 (CD1a, CD1b, and CD1c) glycoproteins expressed on immature and mature dendritic cells present nonpeptide
antigens (i.e., lipid or glycolipid molecules mainly of microbial origin) to T cells. Cytotoxic CD1-restricted T lymphocytes
recognizing mycobacterial lipid antigens were found in tuberculosis patients. However, thanks to a complex interplay between
mycobacteria and CD1 system, M. tuberculosis possesses a successful tactic based, at least in part, on CD1 downregulation to evade
CD1-dependent immunity. On the ground of these ﬁndings, it is reasonable to hypothesize that modulation of CD1 protein
expression by chemical, biological, or infectious agents could inﬂuence host’s immune reactivity against M. tuberculosis-associated
lipids, possibly aﬀecting antitubercular resistance. This scenario prompted us to perform a detailed analysis of the literature
concerning the eﬀect of external agents on Group I CD1 expression in order to obtain valuable information on the possible
strategies to be adopted for driving properly CD1-dependent immune functions in human pathology and in particular, in human
tuberculosis.
1.Introduction
Cell-mediated immunity involved in host resistance against
mycobacteria and other infectious agents appears to rely to
a large extent on classical HLA-restricted responses against
microbial peptides [1] mediated mainly by interferon (IFN)
γ-producing T-cells [2]. However, in recent years grow-
ing attention has been given to T-cell-mediated responses
directedagainstlipidorglycolipidantigenspresentedbyfour
relatively nonpolymorphic CD1molecules ([3–5], reviewed
in [6]).
Two groups of CD1 isoforms expressed on the cell
membrane of various antigen-presenting cells (APCs) have
beenidentiﬁedinthecourseofthelast20years.Inparticular,
Group I (i.e., CD1a, CD1b, CD1c) and the isoform CD1e,
that is conﬁned to the intracellular compartment and is clas-
siﬁedasGroupIIIbysomeauthors,aredetectableinmanbut
not in mice. On the contrary, Group II (i.e., CD1d, a biologi-
calentityoutsidethescopeofthepresentreview)isexpressed
in mice and men as well, and is involved in Invariant Natural
Killer T-cell responses (speciﬁcally reviewed in [7]). The
molecular structure of CD1 is similar to that of MHC class
I. Both CD1 and MHC class I are comprised of heavy chains
ofsimilar length,whichareorganized into three extracellular
domains (α1, α2, and α3) and bind β2 microglobulin.
Group I CD1 molecules are expressed most promi-
nently on APCs of the myeloid lineage, including dendritic
cells (DCs) derived from circulating monocytes (MOs).
Peripheral blood CD1−/CD14+ MOs can be activated by
granulocyte-macrophage colony stimulating factor (GM-
CSF) alone or more eﬃciently in combination with
interleukin-4 (IL-4) (i.e., GM-CSF + IL-4, hereafter referred
to as G4) to express Group I CD1 glycoproteins [9, 10].
These molecules are the products of the CD1A,- B,a n d-C
genes and are known to be involved in the presentation
of nonpeptide microbial antigens to T-cells [6, 10–12]. In
particular, Beckman et al. in 1994 [13] discovered that
the CD1b-presented antigens obtained from Mycobacterium2 Clinical and Developmental Immunology
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Figure 1: Dendritic Cell (DC) generation and maturation. Schematic drawing depicting the diﬀerentiation of monocytes to immature DC
(iDC), generation of mature DC (mDC) and cytokines involved in these processes. Dotted lines point to the modulating eﬀects of external
agents.
tuberculosis were mycolic acids, that is, lipids associated with
microbial cell wall. Later, it was demonstrated that CD1
molecules are competent for presentation of a great variety
of microbial antigenic lipid structures to T-cells, so that CD1
could be tentatively considered a wide spectrum system of
anti-infectious immune surveillance [6].
Particular attention of the present review is dedicated
to the studies concerning the CD1 system predominantly
engaged in antitubercular responses, and therefore involved
in mycobacterial lipid presentation to CD1-restricted T-cells.
A fraction of responder T-cells comes from the CD4−/CD8−
phenotypicsubsetofCD3+ T-cellreceptor(TCR)α/β T-cells.
These cells, sometimes referred to as double-negative TCR
α/β Tl y m p h o c y t e s[ 14], proliferate and generate cytotoxic
clones following interaction with mycobacterial glycolipids,
presented by CD1b+ DCs-derived from G4-preactivated
MOs. However, CD1-restricted CD8+ or CD4+TCR α/β T-
cell clones [15,16]andT CRγ/δ T-cells [3,17]havealsobeen
demonstrated. Thus, responder cells that potentially play
a role in CD1-restricted responses to nonpeptide antigens,
have been found to belong to all of the major phenotypic
subsets of T-cells. Noteworthy is the general observation
that CD1-restricted recognition of bacteria-associated lipids
results in killing of the infected cells as well as of the
microorganism, thus providing presumably a way to prevent
infection spreading in the host [15, 18].
The induction of eﬀector T-cells against microbial anti-
gens is accompanied by the presence of autoreactive CD1-
restricted T-cells directed against self-lipid antigens [19].
These lymphocytes appear to cooperate in early suppression
of invading microorganisms, in the induction of CD1-
restricted memory T-cells and in the maturation of DCs
able to produce substantial amounts of IL-12. In turn, IL-
12 stimulates T-cells to produce IFNγ (reviewed in [20])
and plays an important role in antitubercular immunity
[21]. Autoreactive CD1-restricted T-cells have also been
accused to take part in the immune mechanisms under-
lying multiple sclerosis (MS) and Guillan-Barre syndrome
[22, 23]. However, detection of autoreactive cytotoxic T
lymphocytes in patients aﬀected by autoimmune disease,
does not necessarily mean that these cells play a role in the
pathological events aﬀecting target organs.
Up to now, it has not been deﬁnitely established whether
tuberculosis prevention could be achieved through vaccinial
procedures based on M. tuberculosis-associated lipids as
sensitizing agents. Improvement in the course of the dis-
ease has been noted in guinea pigs sensitized with lipid
extracts of M. tuberculosis [24, 25]. Moreover, a recent study
published by Felio et al. [26] showed that human Group I
CD1 transgenic mice are competent for mounting a CD1-
restricted adaptive immune responses to mycobacteria,t h u s
allowing further preclinical investigations on lipid-based
antitubercular vaccines in mouse models.
In view of a potential role of Group I CD1 glycoprotein-
dependentpresentationofmycobacteriallipidstoT-cells,itis
reasonable to hypothesize that pharmacological or biological
agents able to modulate CD1 expression could modify host’s
responses against infectious diseases, including infections
caused by M. tuberculosis. Therefore, the aim of the present
short survey is to illustrate the data presently available in
the literature, relative to the inﬂuence that can be exerted
by external agents on Group I CD1 molecule expression. In
particular, the reported studies will consider human MOs
driven in vitro or in vivo to diﬀerentiate into immature
and thereafter mature DCs (Figures 1 and 2)c o m p e t e n tf o r
peptide or nonpeptide molecule presentation to T-cells.
2. In Vitro and In Vivo Assays of CD1 Induction
A classical experimental design to explore the functional
pathways involved in the diﬀerentiation and maturation of
human myeloid DCs in vitro system, starting from puriﬁed
CD14+ MOs obtained from peripheral blood mononuclear
cells (PBMNC), can be described as follows (Figure 2):
Step 1. In vitro cultivation of MOs with G4 for 3–6 days (or,
in some cases, for up to 7 days). This treatment is able to
induce “immature DCs” (iDCs) showing high expression of
CD1a, CD1b, and CD1c glycoproteins on cell membrane,
competent for lipid antigen presentation to CD1-restricted
T-cells.Clinical and Developmental Immunology 3
Experiment design (ED) codes 
Type of  Code Exposure to external agents (EA)  CD1 assay
1 ED-1
ED-2
ED-3
ED-4
Step 1 only (initial differentiation pathway)
2 Step 2 only (iDCs maturation to mDCs)
3S t e p  1 o n l y
4 Step 1 + step 2
5E A   in vivo  on tissue iDC or mDC
6 OED Other experimental design (to be detailed in the
“observations” section of the tables ) 
on iDC or mDC
LPS (TNF, IFNs)
STEP 1 STEP 2
CD1 assay  CD1 assay 
EA                                       EA
EA  
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IvDC
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n
Figure 2: Eﬀect of external agents on group I CD1 glycoprotein expression.
Step2. InvitrocultureofiDCswithlipopolysaccharide(LPS)
and/or various cytokines (e.g., TNFα,I F N α,T G F β,e t c . )f o r
additional 2-3 days, leading to mature CD83+ DCs (mDCs),
fully competent to behave as classical APCs.
In a large number of studies published in more than 15
years,iDCshavebeenalsogeneratedfromcordbloodCD34+
cells cultured in vitro with a cocktail of cytokines containing
GM-CSF. In addition, several investigations have been con-
ducted in vivo by evaluating the number of DCs in various
organs, in diﬀerent clinical and treatment conditions using
immunohistochemical detection of mainly CD1a+ cells.
All these methods, able to explore the functional path-
ways leading to mDCs, allowed to test the eﬀect of a number
of exogenous agents on the expression of Group I CD1
molecules induced in host’s cell population involved in
resistance against pathogens, including mycobacteria.
I no r d e rt oo ﬀer a concise picture on the external control
of CD1 expression, the present review provides information
on the complex relationship between mycobacteria and CD1
levels, and four tables summarize schematically what we
presently know on the regulation of CD1 expression by
pharmacological and biological agents. Moreover, with the
intent to provide a simpliﬁed information on the experi-
mental strategy utilized for studying the inﬂuence exerted by
exogenous agents on CD1 expression during myeloid DCs
induction and maturation, we decided to adopt the codes
that are illustrated in Figure 2.
3. CD1 Expression
It is generally agreed that transcriptional control of gene
expression and posttranscriptional regulation of mRNA
function are usually under the control of proteins targeting
speciﬁc DNA sequences (i.e., transcription factors) and
microRNAs, respectively. In particular, expression of Group
I CD1 genes is under the control of transcription factors,
that have been described in detail for CD1a glycoprotein by
Colmone et al. [27]. A minimal 1000-bp region upstream of
the translation start site has been identiﬁed as necessary for
proximal promoter activity required for CD1A transcription.
This region contains multiple sites that were considered
to be coordinatively involved in CD1A gene expression on
the basis of a series of experiments performed by means
of deletion and site-speciﬁc mutant analysis. In particular,
ac r i t i c a lr o l ea p p e a r e dt ob ep l a y e db yap o t e n t i a lc A M P
response element (CRE), 965bp upstream of the CD1A
translation start site. It was found that the CRE-binding
protein 1 (CREB-1) and the activating transcription factors-
2 (ATF-2) that are enlisted among the ATF/CREB family
members, are able to bind this site in vitro and in vivo in
various cell types, including human MOs [27]. Moreover,
the results of these studies speak in favour of ATF-2-induced
inhibition counterbalanced by a stimulatory activity on gene
transcription by CREB-1, possibly through a competition
of CREB-1 and ATF-2 for CRE binding. The hypothesis
of opposite control performed by two transcription factors
acting on the same gene promoter appears to be supported
by the studies published by Niwano et al. [28]w h op r o p o s e d
a similar mechanism for endothelial nitric oxide synthase.
In the present survey of the literature, we noticed the
emerging role played by miRNAs on hematopoiesis (revie-
wed in [29]). Therefore, we have considered the possibility
that miRNAs could aﬀect CD1 expression. An in silico ana-
lysis was performed using the miRanda (http://www.mic-
rorna.org/)andT argetScan(http://www.targetscan.org/)alg-
orithms for miRNA target prediction. Under miRanda4 Clinical and Developmental Immunology
analysis, miRNA list indicates conserved miRNAs with good
mirSVR scores [8]. As illustrated in Table 1, this analysis
revealed that mRNAs transcribed from all three Group I
CD1 genes can be targeted and potentially regulated at
the 3 UTR region by a number of diﬀerent miRNAs. In
particular, 10 miRNAs have been found to share a potential
capability of controlling the transcriptional activity of two
CD1 genes. Six miRNAs (i.e., 33a, 33b, 421, 495, 590-3p,
and 590-5p) could target both CD1a and CD1c, whereas
miRNA-224 could be active on CD1a and CD1b, and 3
miRNAs(i.e.,129-5p,185and203)appeartobetheoretically
c o m p e t e n tt ot a r g e tC D 1 ba n dC D 1 c .H o w e v e r ,u pt on o w
no study able to validate the in silico prediction patterns is
available from the literature. Nevertheless, a number of miR
genes have been found to be involved in the regulation of
immune responses [30, 31] and acute inﬂammation [32].
Moreover, quite recently Kuipers et al. [33] described that
microRNAs control maturation, function, and maintenance
ofDCsintheepidermis(i.e.,Langerhanscells,LC)invivo.I n
addition, exchange of genetic material between prokaryotic
and eukaryotic multicellular organisms has been described
[34]. Therefore, since pathogenic microorganisms, including
mycobacteria contain a large amount of small noncoding
RNA [35, 36], it is reasonable to hypothesize that invading
microbes could control gene expression of host eukaryotic
cellthroughtheirmiRNA-likemoleculestoacquireasurvival
advantage.
4. Mycobacteria andCD1 Expression
Anti-tubercular immunity relies on humoral and cell-
mediated immune responses against M. tuberculosis-
associated epitopes of various origin, and possibly includes
CD1-presented lipid antigens recognized by dedicated T-cell
subpopulations [37]. More than eighty years ago, attenuated
strains of M. bovis (i.e., Bacillus Calmette-Guerin, BCG)
were developed and utilized as antitubercular vaccine,
since they share a variety of antigenic molecules with
virulent pathogenic bacilli [38]. Although BCG vaccine
reduces the risk of severe forms of tuberculosis in early
childhood, unfortunately it is not very eﬀective in preventing
the pulmonary infection in adolescents and adults, the
populations with the highest rates of tuberculosis disease.
Moreover, M. tuberculosis is changing and evolving, making
the development of new vaccines [39]m o r ec r u c i a lt o
control the disease that is continuously expanding, favored,
at least in part, by AIDS pandemia.
In the last years, a considerable amount of experimental
studies has been dedicated to investigate the complex rela-
tionship between the infection with virulent M. tuberculosis
or BCG and functional activity of the CD1 system. A
number of studies conﬁrm that lipid antigens recognized
and presented by Group I CD1 glycoproteins include fatty
acids isolated from M. tuberculosis cell wall [40]. Among
others,theycomprisethefatty-acid-derivedmycolicacid,the
lipopeptide didehydroxymycobactin [41], the isoprenoid-
like structure mannosyl phosphomycoketide [42], and the
acylated sulfoglycolipid Ac2SGL [43].
Table 1:miRNAswithputativebindingsitesinthe3 UTRofCD1A,
CD1B, and CD1C genes.
Gene Algorithm
miRandaa Target Scanb
CD1A
19a, 21, 28-5p, 31,
33a, 33b, 146a,
146b-5p, 214, 217,
361-5p, 383, 421, 448,
495, 590-3p, 590-5p,
708, 873
21, 28-5p, 31, 33a,
33b, 125a-3p, 138,
146a, 146b-5p, 197,
205, 224, 421, 448,
495, 590-5p, 708
CD1B 129-5p, 137, 185, 203,
224, 543 129-5p, 137, 203, 543
CD1C
26a, 26b, 33a, 124,
125a-5p, 125b,
129-5p, 181a, 181b,
181c, 181d, 190, 190b,
203, 216a, 216b, 218,
219-5p, 300, 326,
330-5p, 340, 367,
376a, 376b, 381, 410,
421, 433, 455-5p, 494,
495, 505, 506, 539,
543, 590-3p, 1297
22, 26a, 26b, 33a,
33b, 124, 125a-5p,
125b, 129-5p, 132,
185, 190b, 203, 212,
216a, 216b, 218,
219-5p, 221, 222, 300,
326, 330-5p, 376a,
376b, 410, 495, 425,
433, 455-5p, 489, 494,
505, 506, 539, 542-3p,
543, 590-5p, 599,
1297
aConserved miRNAs with good mirSVR scores [8].
bmiRNAs broadly conserved among vertebrates (bold) or conserved only
among mammals.
In this context, CD1b appears to play a particularly
important role, since CD1b-restricted T lymphocytes recog-
nize a large variety of mycobacterial lipids [44], including
M. tuberculosis Ac2SGL antigens [45]. Moreover, CD1b
groove is much larger than that associated with the other
CD1 isoforms, so that it can adjust long chain foreign
lipids, including long mycobacterial mycolates that are not
presented by the other CD1 molecules [46]. On the basis
of all these ﬁndings and taking into account additional
information from the literature (reviewed in [6, 46]), it is
reasonable to consider Group I CD1 as a relevant part of the
complex antigen-presenting systems involved in the T-cell-
dependent immune response machinery against mycobac-
teria. Actually, in human leprosy lesions CD1 expression
correlates with host immunity as manifested by active
cellular immunity to M. leprae [47]. A number of clinical
and experimental data indicate that long-lived immunity to
M. tuberculosis relies largely on antigen-speciﬁc CD4+ and
CD8+ T-cells that could play consistent roles in vaccination
strategies [48]. Therefore it is reasonable to hypothesize
that CD1-restricted eﬀector T lymphocytes, that show a
limited repertoire but are able to recognize large amounts
of lipid antigens based on antigenic cross-reactivity [49],
would contribute to antitubercular immunity. Ulrichs et
al. [50] collected PBMNC from patients with pulmonary
tuberculosis, from asymptomatic individuals with known
contact with M. tuberculosis documented by conversion of
their tuberculin skin tests, and from healthy tuberculin skin
test negative subjects. In vitro, in presence of autologous
CD1+ iDCs, the extent of CD1-restricted T-cell responses
to a lipid extract of M. tuberculosis was tested by meansClinical and Developmental Immunology 5
of proliferation and IFNγ production by eﬀector T-cells.
The results showed that T-cells from asymptomatic M.
tuberculosis-infected donors were signiﬁcantly more respon-
sive than those obtained from uninfected healthy donors.
Moreover, essentially no CD1-restricted T-cell response was
detectable in lymphocytes collected from patients with active
tuberculosis prior to chemotherapy. However, signiﬁcant
antilipid immune reactivity became detectable in blood
samples drawn two weeks after the start of treatment, as a
possible consequence of chemotherapy-induced relief of the
inhibitory eﬀect exerted by mycobacteria on cell-mediated
immunity [51].
In order to better deﬁne the possible role that can be
played by CD1-dependent antimycobacterial immunity, it is
important to identify the target of CD1-restricted eﬀector
T-cells and the modality of target suppression. Of note are
the ﬁndings illustrated by Vincent et al. [52]w h ou s e dC D 1 -
restricted human α/β T-cells generated by autologous DCs in
presenceofmicrobialdetergentextractsfromM.tuberculosis,
E. coli,o rY. enterocolitica.E ﬀector T-cells were found to be
active in terms of proliferation and IFNγ release when tested
against target cells presenting microbial lipid antigens via
CD1a, CD1b, or CD1c molecules. However, similar activity,
although to a lower extent, was detected in absence of
foreign lipids, thus indicating that sensitized lymphocytes
were also endowed with eﬀector function against self-lipids.
The authors propose that CD1-restricted T lymphocytes ﬁt
in two T-cell populations, that is, naive T lymphocytes able
to mount an adaptive response to microbial lipids as well
as memory/eﬀector T-cells. The latter population, charac-
terized by reactivity against self and foreign lipids, would
be particularly dedicated to rapid initial immune responses
against invading pathogens and yet able to undergo clonal
expansion responsible for long-standing cellular memory
to foreign lipid antigens. Actually, Nguyen et al. [53]h a v e
recently reported that upon experimental vaccination of cat-
tle, CD1b-restricted memory T-cell response can be elicited
by the mycobacterial glycolipid glucose monomycolate.
The eﬀector function of T lymphocytes against micro-
bial targets, including M. tuberculosis follows a rather
complex pattern (reviewed in [20]). When primed T-cells
interact with CD1+ mycobacteria-infected target cells, they
kill directly mycobacteria through granulysin/perforin-based
mechanism release [54], or they induce Fas-dependent
apoptoticdeathoftargetcellswithoutkillingtheintracellular
infectious agent. In this case mycobacteria are released
and infect adjacent macrophages and DCs where invading
bacilli are possibly killed, depending on microbial burden.
In addition to direct cytotoxic eﬀects, CD1-restricted T-
lymphocytes release Th1 cytokines (i.e., IFNγ and TNFα)
that activate the microbicidal functions of macrophages and
DCs [20].
Recently, the role of IFNγ released by CD1-restricted
eﬀector T-cells has been subjected to detailed analysis by
Lee and Kornfeld [55]. These authors reported that IFNγ
released by T-cells inhibits bacterial replication in infected
macrophages carrying low intracellular burden of mycobac-
teria, thus contributing to host defenses against tuberculosis.
However, when macrophages are engulfed with high bacteria
load,IFNγ facilitateshostcelldeath,thuspromotingnecrosis
and spreading of the infection, with potentially adverse
eﬀects on the course of the disease.
A large body of experimental data is presently available
fromtheliteratureshowingthatmycobacteriahavedeveloped
highly sophisticated strategies to escape host’s resistance
based either on innate or adaptive immunity (reviewed
in [56]). Tuberculosis is predominantly a lung disease
characterized by long chronic course due to persistent and
sometimes dormant infection. It is well documented that
upon contact with inhaled M. tuberculosis, both alveolar
macrophages, that do not express CD1 molecules, and CD1+
DCs phagocytose mycobacteria. B u tm o s to ft h em i c r o o r -
ganisms are taken up by macrophages that are by far more
eﬃcient than resident lung DCs in the ability to phagocytose
and possibly kill bacteria [57]. However, the fate of M.
tuberculosiswithintheinfectedalveolarmacrophagedepends
on the state of activation of the phagocyte. Actually, the
bacillus is able to survive preferentially within a macrophage
subpopulation displaying an anti-inﬂammatory phenotype
with a reduced oxidative burst. Moreover, phagocytosed
mycobacteria end up in a phagosome, the maturation of
which is arrested at an early stage [58], at least in part by
mycobacteria-released glycolipids, such as lipoarabinoman-
nan and phosphatidylinositol mannoside [59]. M. tubercu-
losis inhibits phagosomal acidiﬁcation, prevents phagosome-
lysosome fusion and survives within macrophages by avoid-
ing lysosomal delivery thanks, at least in part, to coronin
1 that is actively recruited to mycobacterial phagosomes
[60]. Since alveolar macrophages do not express CD1
molecules, and mycobacterial peptide antigens conﬁned
to phagosomes are excluded from the classical MHC-I
presentation pathway, they cannot be targeted by MHC-
I- or CD1-restricted cytotoxic lymphocytes. Therefore, in
the lung environment, host’s defenses against mycobacte-
ria are mainly activated through apoptosis induction of
infected alveolar macrophages followed by cross-priming
of resident DCs endowed with the appropriate machin-
ery for peptide and lipid/glycolipid antigen presentation
to T-cells [61]. However, mycobacterial infection inhibits
speciﬁcally macrophage apoptosis [62], thus preventing DC
cross-priming and consequently providing an additional
mechanism of impairment of host’s T-cell defenses based on
bacterial antigen recognition.
Infection with M. tuberculosis can also adversely aﬀect
DC function by interfering with their expression pattern
of antigen-presenting molecules. Therefore, among the
diﬀerent escape mechanisms operated by mycobacteria,o f
particular relevance for the present survey are the complex
autocrine and paracrine devices that the microorganism uses
tocontroltheinductionofGroupICD1moleculeexpression
ininfectedandadjacentnoninfectedMOs.In1998Stengeret
al. [63]e x p o s e din vitro MOs from healthy donors to G4 for
3 days, obtaining iDCs expressing high levels of Group I CD1
glycoproteins.Thereafter,iDCswereheavilyinfectedwithM.
tuberculosisthatwasabletosuppressentirelyCD1expression
within 24h independently from any cytokine intervention.
Ontheotherhand,Preteetal.[64]reportedlaterthatinvitro
coculture of BCG with untreated MOs was able to induce6 Clinical and Developmental Immunology
GM-CSF release by infected cells leading to limited CD1b
expression. Modest upregulation of Group I CD1 antigen
expression was also described by Roura-Mir et al. [65]i n
untreated MOs after in vitro infection with M. tuberculosis
at 2 or 10 bacteria per cell. These authors report that their
ﬁndings could be explained, at least in part, through Toll-like
receptor-2 (TLR-2) signaling induced by mycobacterial cell
wall lipids. A possible, although limited induction of CD1
expression by mycobacteria has also been described in vivo.
Videira et al. [66] found that prophylactic administration
of intravesical BCG to prevent tumor recurrence in bladder
cancer patients, was followed by upregulation of CD1A,
CD1B, CD1C, and CD1E gene transcripts in cells obtained
fromurotheliumbiopsies.Thiseﬀectwassigniﬁcantlyhigher
in patients with a more favorable response with respect
to that observed in patients with early tumour recurrence
[66]. Marked accumulation of CD1a+ LC after mycobacterial
stimuli was also described in leprosy skin lesions [67]. On
the other hand, in vitro maturation of MOs to CD1a+
DCs under the inﬂuence of G4 and LPS was found to be
sensibly impaired when MOs were collected from patients
with pulmonary tuberculosis [68]. The intriguing Janus-
like behavior of mycobacteria relative to CD1 expression has
been investigated in 2001 by Prete et al. [69] and Giuliani
et al. [70], who found that BCG induced in vitro a limited
expression of CD1 in untreated MOs from healthy donors,
but inhibited markedly G4-induced CD1 upregulation in
the same cells. Thereafter, further investigations conﬁrmed
that in vitro infection with mycobacteria downregulates CD1
expression [71, 72]. In particular, upon exposure to G4,
MOs infected with M. smegmatis failed to express CD1a and
evolved directly into CD83+ mDCs [73]. In 2007, Prete et
al. [74] provided direct experimental evidence that in vitro
exposure of healthy MOs to BCG induced release of both
GM-CSF and IL-10, and that the interplay between the two
cytokines was presumably involved, at least in part, in the
Janus-like behavior of BCG. Actually, early GM-CSF release
was responsible for the limited autocrine and paracrine CD1
induction. On the other hand, slightly delayed appearance
in culture medium of IL-10 produced by BCG-infected MOs
contributed to the severe limitation of further increase of
CD1 proteins, even in the presence of exceedingly high
concentrations of added GM-CSF. More recently, Gagliardi
etal.[75]reportedthatmycobacteriatriggerphosphorylation
of p38 mitogen-activated protein kinase (p38 MAPK) in
human MOs, leading to CD1 expression impairment. In
fact, pretreatment with a speciﬁc p38 MAPK inhibitor allows
infected MOs to diﬀerentiate into CD1+ DCs, which are
fully capable of presenting lipid antigens to speciﬁc T-cells.
Further studies have been conducted on the possible role of
cytokines in restraining the GM-CSF-induced upregulation
of Group I CD1 glycoproteins in mycobacteria infected MOs.
Quite recently, Remoli et al. [76] conﬁrmed the results
of the studies described by Prete et al. [74] showing that
IL-10 produced by MOs infected with M. tuberculosis is
responsible for in vitro suppression of CD1. Moreover,
consistently with the results obtained previously by the same
group [75], they suggested that IL-10 release by infected
MOs was induced by the activation of p38 MAPK signal
transduction pathways. Several reports from the literature
indicate that mycobacteria activate IL-10 gene and promote
IL-10 release from MOs, phagocytes, and DCs through
diﬀerent intracellular pathways, including PI3K/AKT and
p38 MAPK [77–81], phosphorylation and activation of
dsRNA-activated serine/threonine protein kinase [82]a n d
glycogen synthase kinase 3 [83]. Noteworthy is the role of
proline-glutamic acid/proline-proline-glutamic acid family
of proteins of M. tuberculosis that can stimulate macrophages
tosecreteIL-10viaactivationoftheTLR-2leadingtoanearly
and sustained activation of p38 MAPK, which is critical for
IL-10 induction [84]. The role of MAPK in the impairment
of CD1 expression by mycobacteria has been also conﬁrmed
andemphasizedveryrecentlybyBalboaetal.[85]whofound
that mycobacteria-induced loss of CD1b molecules partially
involves TLR-2/p38MAPK activation.
Several other molecular mechanisms distinct from those
relative to impairment of CD1 gene transcription could be
involved in mycobacteria-induced decrease of CD1 expres-
sion or of antigen presentation eﬃciency. The complex
cycle of CD1 biosynthesis, cell surface expression, and
lipid loading [12, 44, 86] highlights the several means by
which mycobacteria can interfere with CD1 expression on
cell membrane and antigen presentation to T-cells. After
biosynthesis in the endoplasmic reticulum, CD1e remains
in the cell, whereas all other CD1 molecules reach the cell
surface through the Golgi and trans-Golgi network where
they bind to self-lipids. Direct loading of lipids may occur
at the plasma membrane, as described for glycosphingolipids
that bind to CD1b on the cell surface at neutral pH.
Thereafter, glycosphingolipids are recognized without inter-
nalization or processing and stimulate speciﬁc T-cells [87].
Moreover, various cell-surface CD1a proteins are stabilized
by exogenous glycosphingolipids and phospholipids present
in serum [88].
As a rule, processing and presentation of microbial
CD1-bound lipid antigens require that CD1 molecules,
loaded with self-lipids, undergo a recycle process. CD1-
self lipid complexes are internalized, traﬃc through the
endosomal compartments, where loading and/or exchange
with exogenous lipid antigens occur, then the new CD1-
nonself lipid complexes re-emerge on plasma membrane.
This process resembles peptide sampling by MHC class
II proteins, although MHC class II molecules may reach
the endocytic compartment directly from the trans-Golgi-
network, without ﬁrst travelling to the cell membrane.
Cell surface CD1 molecules are internalized according
to two distinct mechanisms. Speciﬁcally, CD1a molecules,
which lack a tyrosine-based internalization motif, are
internalized to the early endosomes [89] through a
clathrin/dynamin-independent manner and recycle back to
the plasma membrane through a mechanism that relies on
small GTPases, such as Rab22 and ADP-ribosylation factor
6. Both CD1b and CD1c molecules, instead, have a tyrosine-
based motif in their cytoplasmic tail and are internalized
through clathrin-coated pits via the adaptor protein 2 (AP-
2). Thereafter, CD1b is transported to the late endosomes
and, after binding to AP-3, traﬃcs to the lysosomes and then
recycles to the plasma membrane. On the other hand, CD1c,Clinical and Developmental Immunology 7
after reaching the sorting endosomes, routes to the early
endosomes, and, although to a lesser extent, to the late endo-
somes and lysosomes, and then recycles to the plasma mem-
brane. It follows that CD1c operates a comprehensive survey
for lipid antigens throughout the endocytic system [90].
The entire CD1 recycling pattern reveals that a large
variety of molecular targets could be aﬀected by M. tuber-
culosis. In addition to that, it must be considered that
intracellularlipidloadingpresumablyrequiresthefunctional
intervention of a number of helper and adaptor molecules,
including saposins and apolipoproteins [91, 92] and CD1e
itself [93, 94]. Moreover, acidic pH promotes lipid binding
to CD1b proteins, thus suggesting that pH ﬂuxes during
endosomal recycling regulate the conformation of the CD1
heavy chain to control the size and rate of antigen capture
[95]. Within this context, it is worth of note the ﬁnding
that mycobacteria impair phagosome acidiﬁcation [58]t h u s
reducing the extent of mycobacterial lipids bound to CD1b
for T-cell presentation.
5. HIVandCD1 Expression
Interestingly enough, not only the mycobacterial infection,
butalsoHIVorHTLV-1infectionorintracellularpresenceof
HIV products are able to interfere with CD1 expression. For
example, HIV-1-Nef was found to interfere with the intra-
cellular traﬃcking of CD1a [96], although recombinant Nef
added to iDCs increases CD1a expression [97]. Moreover, it
must be pointed out that viable HIV-1 particles infect target
CD4+ T-cells via CD1b+ exosomes [98]. On the other hand,
in 30 to 45% of HIV-infected white and African subjects,
peripheral blood MOs exposed in vitro to G4 followed by
LPS gave rise to CD1a− mDCs releasing IL-10 but not IL-12
[99]. In addition, DCs from HTLV-I-infected monocytes fail
to present adequate amounts of CD1a glycoprotein [100].
Preliminary investigations of experimental design (ED)-
1 type (see ED codes illustrated in Figure 2)p e r f o r m e d
in our laboratory, revealed also a possible link between
HIV infection and CD1 system, presumably relevant to
the increased susceptibility of HIV-infected individuals to
mycobacteria.Avectorexpressingtat DNA(PCV-TAT,[101])
under the control of the major adenoviral late protein, and
a control empty vector (PCV-0) were kindly provided by
BarbaraEnsoliMDoftheItalianNationalInstituteofHealth.
Peripheral blood MOs of healthy donors were incubated
with G4 alone or with G4 + a supernatant obtained from
the human T-cell leukemia line Jurkat transfected with
PCV-0 (sup-PCV-0) or with PCV-TAT (sup-PCV-TAT). The
results of a representative experiment demonstrated that tat-
inducedfactorsreleasedbytransfectedcellsareabletodown-
regulate CD1b expression. In fact, after 5-day exposure to
G4 in vitro, iDCs generated in the absence of supernatants
or in the presence of sup-PCV-0 showed 72% and 79%
CD1b+ cells, respectively. In contrast, when iDCs were
generated in the presence of sup-PCV-TAT, the percentage
of CD1b+cells dropped signiﬁcantly to 54% (Franzese et al.,
in preparation). Moreover, if monoclonal antibodies against
IL-10 were added to G4 + sup-PCV-TAT at the onset of iDC
generation, the percentage of CD1b+ cells raised to 81%.
These results along with previous ﬁndings indicating that
TAT induces IL-10 in MOs [102] and that IL-10 downreg-
ulates CD1 expression [74–76, 103–106], are consistent with
the hypothesis that IL-10, generated in the presence of TAT,
plays a critical role in compromising CD1b expression.
6. Chemical, Biological, andPhysicalAgents
Affecting CD1 Expression
6.1. Drugs. A number of natural and synthetic compounds
of pharmacological interest are able to modulate the expres-
sion level of Group I CD1 proteins on immature and/or
matureDCs,eitherinvitroandinvivo,asreportedinTable 2.
As expected, most of the immunosuppressant and anti-
inﬂammatory agents, including corticosteroids, nonsteroidal
anti-inﬂammatory drugs (NSAID), and anti-asthma com-
pounds, down-regulate cytokine-induced CD1 expression of
MOs and impair their functional activity. However, local
application of Pimecrolimus on skin in atopic dermatitis, is
followedbyincreaseinthenumberofCD1a+ cells.Moreover,
in vitro exposure of CD34+ peripheral blood progenitor
cells to Tacrolimus favors the expression of CD1a induced
by 14-day treatment with cytokines. Notable exceptions to
the inhibitory eﬀects of anti-inﬂammatory drugs is also
represented by Piceatannol (a stylbene compound similar to
resveratrol) and terpenes that were found to increase CD1a
expression after G4 treatment in vitro of MOs obtained from
healthy donors. Of sensible relevance to the problem of MS
therapy andidentiﬁcation of disease pathogenesis is the ﬁnd-
ing that Glatiramer acetate (GA), alone or in combination
with IFNβ, is able to down-regulate CD1 expression in vitro
or in vivo. Similar inhibitory eﬀects have been described in
vitro with vitamin D3 that shows beneﬁcial eﬀects in MS
management. These observations appear to provide further
support to the hypothesis that signiﬁcant participation of
CD1-restricted T-cell responses against self lipid antigens is
involved in the neuronal damage occurring in MS.
Among chemotherapeutic agents, antitubercular (rifam-
picin) or antiretroviral (entecavir) drugs tend to up-regulate
CD1 expression, whereas zidovudine (AZT), that inhibits
iDC proliferation, diminishes the overall availability of
CD1a+ cells. In the area of antineoplastic therapy, reduction
of cytokine-induced CD1 levels by various agents is the
dominant ﬁnding, as shown in vitro by histone deacetylase
(HDAC) inhibitors, tyrosin kinase inhibitors (i.e., imatinib
and sorafenib) and antiestrogens, and in vivo by thalidomide
in multiple myeloma (MM) patients.
More diﬃcult to interpret is the activity of a classical
agent largely utilized in mood disorders including bipolar
aﬀective disorders, such as lithium. The drug downregulates
the in vitro cytokine-induced CD1a expression in MOs of
healthy donors. However, limited CD1a expression is elicited
by G4 in MOs collected from patients with bipolar disorders.
In this case, in vivo treatment of donor patients with lithium
restores full responsiveness of their MOs to G4 exposure in
vitro.
6.2. Cytokines and Autacoids. Table 3 illustrates the limited
information available from the literature on the eﬀect8 Clinical and Developmental Immunology
Table 2: Pharmacological modulation of CD1 molecule expression.
Drug class Agent Therapeutic use CD1a ED
b Ref
c Observations
Angiotensin
receptor
antagonists
Losartan
(AT1-R)
PD123319
(AT2-R)
Hypertension D
U
ED-1
ED-1 [107] Assay performed on day 7.
Anti-asthma Suplatast
tosilate
Inhibitor of
Th-2 responses D ED-1
ED-2 [108] In ED-1 the assay was performed on day 7.
DCs were obtained from pts with asthma.
Anti-depressant Lithium Bipolar
disorders
DE D - 1 [ 109] MOs, obtained from bipolar pts, were
incubated with G4.
UI v D C [ 109]
In vitro generated DCs from lithium-treated
pts showed higher CD1a expression than DCs
from untreated pts.
DE D - 1 [ 110] Mechanism: CD1 down-regulation is likely
mediated through the GSK-3β pathway.
Anti-estrogens Tamoxifen
Toremifene Breast cancer D ED-1
ED-2 [111] Assay performed on day 7.
Anti-
inﬂammatory
corticosteroids
Beclomethasone
dipropionate
(BDP, inhaled)
Asthma D IvDC [112]
In bronchial mucosa of asthmatic pts there is
an increase of CD1a+ DCs. Following
long-term treatment with BDP the number of
CD1a+DCs went to normal levels of
non-asthmatic pts.
Dexamethasone
(DEX) Inﬂammatory
diseases
D ED-1
ED-4 [113]
Strong CD1a down-regulation. Mechanism:
high IL-10 via Extracellular signal-regulated
kinases (ERK) phosphorylation.
DO E D [ 114]
CD34+ cord blood stem cells were cultured
with SCS, Flt3-ligand and GM-CSF
(Pre-DC). After 5 days, TNFα and IL-4 were
added (diﬀerentiation stage). On day, 10
CD-40 ligand and anti-human CD40-ligand
were also added (maturation stage). DEX,
added during diﬀerentiation stage, suppresses
CD1a at the end of the immature (day 10)
and at the mature stage (day 12). On the
c o n t r a r y ,C D 1 aw a se x p r e s s e da tn o r m a l
levels when DEX exposure was limited to the
2 day maturation stage.
ED-1
ED-3
ED-4
[115] The MO-derived DCs were obtained from
neonatal cord and adult blood.
Various
including DEX NC OED [116]
CD1a+ cells derived from bronchoalveolar
lavage showed lower APC function if treated
with DEX in vitro.
Anti-tubercular
agents Rifampicin U ED-1 [117]
[118]
Test on CD1b: the drug does not aﬀect the
functional activity of the T-cell clone capable
of recognizing the mycolic acid of M.
tuberculosis origin, presented by CD1b
proteins.
Test on CD1b: eﬀect obtained at clinical
concentration of the drug.
Antiviral AZT
Entecavir
HIV treatment
Hepatitis B
treatment
NC
U
ED-1
ED-1
[119]
[120]
AZT inhibits DC proliferation, thereby
reducing the total number of DCs.
Bisphosphonates Zoledronic acid Osteoporosis D ED-4
ED-2 [121] Mechanism: possibly via IL-10 induction,
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Table 2: Continued.
Drug class Agent Therapeutic use CD1a ED
b Ref
c Observations
Disinfectants Sodium
Chlorate DE D - 1 [ 122]
Sodium chlorate reduces GAG sulfation on
MO surface. Reduction of sulfated CSB
impairs IL-4 mediated DC diﬀerentiation and
CD1a expression.
HDAC inhibitors
MS-275 Sodium
valproate Antitumor D ED-4
ED-1 [123]
Mechanism: NF-kB, IRF-3 and IRF-8
inhibition. Possible use in inﬂammatory and
autoimmune disorders.
Na butyrate D ED-1 [124] The agent prevents CD1 upregulation
induced by activation of TLR-2.
Immuno
stimulant agents
Imiquimod
(imidazo
quinoline)
Topical use in
squamous cell
carcinoma
DI v D C [ 125] In skin biopsies after topical treatment.
OK-432 In cancer
treatment UE D - 2 [ 126]
The maturation step was performed with
OK-432 which promotes a higher expression
of CD1a in respect to that obtained with LPS.
Immuno
suppressive
agents
Gold sodium
thiomalate
(GST)
Rheumatoid
arthritis (RA) D
ED-1
ED-2
ED-4
[127]
DCs were obtained from healthy donors or
RA pts. The suppression of DC diﬀerentiation
and function might explain the in vivo eﬀect
of GST on RA patients.
Glatiramer
acetate (GA) +
minocycline
(MIN)
Multiple
sclerosis (MS) D ED-1
ED-4 [128]
DCs were obtained from untreated and
GA-treated MS pts. The possible additive
eﬀects of GA and MIN on MO-derived DCs,
seem to support the use of such combination
therapy in MS.
GA + IFNβ MS D IvDC [129]
MOs were obtained from untreated or treated
MS pts and from healthy donors.
Combination therapy with IFNβ+G A
resulted in a more pronounced decrease of
circulating CD1a compared to monotherapy
with IFNβ.
MS D ED-1 [130]
Assay was performed on day 7. DC were
obtained from MS pts. Synergistic eﬀects of
GA and IFNβ.
Monomethyl-
fumarate
(MMF)
Psoriasis D ED-1
ED-4 [131]
MMF interfered with the MO-derived DC
diﬀerentiation, resulting in impaired
maturation of these cells.
Pimecrolimus Atopic
dermatitis
NC ED-1 [132]
No interference with the function of DCs,
whereas the activation of eﬀector T-cells was
inhibited.
UI v D C [ 133] In epidermal cells (biopsy) after topical
treatment.
Rapamycin
Immuno-
suppressant
U ED-1
ED-4 [134] Reduction of MHC-I, MHC-II and Ag
uptake.
Sinomenine U ED-1 [135] The drug prevents LPS-induced DC
maturation.
Tacrolimus
(FK506)
D
ED-1
ED-2
ED-4
[136]E ﬀect on LPS-induced DCs in vitro.
DI v D C [ 137] Topical treatment of epidermal CD1a+,i np t s
with atopic dermatitis.
UO E D [ 138]
Generation of DCs from CD34+ peripheral
blood progenitors obtained by culturing the
cells with GM-CSF, TNFα, stem cell factor for
14 days. FK506 was added throughout the
culture starting on day 0.10 Clinical and Developmental Immunology
Table 2: Continued.
Drug class Agent Therapeutic use CD1a ED
b Ref
c Observations
Triptolide Polycystic
Kidney disease D ED-1
ED-2 [139]
Suppression of DC diﬀerentiation and
maturation by triptolide may explain some of
its immunosuppressive properties.
Insecticides Rotenone D ED-1 [140]
Mechanism: increased levels of reactive
oxygen species that seem to trigger the
diﬀerentiation process of DC.
Multidrug
resistance (MDR)
protein
antagonists
MK571[multi
drug resistance
protein 1
(MRP1)
blocker]
PSC833 (P-gp
blocker)
Possible use in
MDR
DE D - 4 [ 141] MRP1 transporter activity is important for
DC diﬀerentiation.
NC OED
Langerhans-like DCs were obtained from
human acute myeloid leukemia cell line
MUTZ-3, cultured with TGF-β1, GM-CSF
and TNFα for 10 days, and MDR antagonists
were added on day 4, 7, and 10.
Monoclonal
antibodies Inﬂiximab Anti-TNFα D ED-1
ED-4 [142]
MOs from psoriasis pts. Reduction of
antigen-presenting capacity of DCs,
proliferation and IFNγ release by psoriatic
T-cells.
NSAID
Acetylsalicylic
acid (ASA) Inﬂammation D ED-1
ED-4 [143]
The new nitric oxide releasing-ASA
(NCX-4040, NCX-4016) did not aﬀect the
expression of CD1a during maturation stage
(ED-4).
Niﬂumic acid
(NFA) Inﬂammation D ED-4 [144]
NFA inhibits LPS-induced DC maturation by
inhibiting co-stimulatory molecule
expression and IL-12p70 production.
Microsomal
triglyceride
transfer protein
(MTP) inhibitors
BMS212122 Anti-lipid D ED-1 [145] MTP inhibitors down-regulate self as well as
exogenous lipid antigen presentation.
NO donors
DEA-NO,
SIN-1,
DETA-NO
U
NC
ED-1
ED-2
ED-1
[146] The drugs are TNFα receptor inhibitors.
Statins Atorvastatin Dyslipidemia U OED [147]
MO-derived DCs were obtained from healthy
donors. MOs exposed to atorvastatin in
combination with IFNα, showed an increased
levels of CD1a compared to IFNα alone.
Lovastatin D ED-2 [148]
DCs were obtained from MS pts. Lovastatin
was added after G4, simultaneously with
TNFα.
TLR agonists
Pam CSK
resiquimod
(R848)
Immune
response
modiﬁer
UO E D [ 149]
Induction of CD1a+ cells in freshly isolated
BM CD34+ progenitor cells cultured with
TLR agonists without cytokines.
Tyrosine Kinase
Inhibitors
Imatinib Antitumor D ED-1
ED-4 [150] In ED-1 the assay was performed on day 7.
Mechanism:N F - kB and AKT inhibition.
DO E D [ 151]
In vitro eﬀects of imatinib, added to the
culture together with diﬀerent cytokines, on
the development of mobilized human CD34+
peripheral blood progenitor cells into DCs.
Sorafenib Antitumor D ED-1 [152] In ED-1 sorafenib was added on day 5.
ED-2 Mechanism: P13MAPK and NF-kB inhibition.
Various
All
trans-retinoic
acid (ATRA)
Various U ED-1 [153] In ED-1 ATRA was associated with GM-CSF
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Table 2: Continued.
Drug class Agent Therapeutic use CD1a ED
b Ref
c Observations
Retinoic acid
(Am80) Various D ED-1 [154]
Am80 treatment ameliorated macro- and
microscopic damage in dextran sodium
sulfate-induced colitis in mice, and
suppressed the colitis induced elevation of
IL-12.
Thalidomide
Multiple
myeloma (MM) DO E D [ 155]
MOs were obtained from peripheral blood of
MM pts treated or not with thalidomide. For
in vitro DCs generation standard cytokines
were used.
Sarcoidosis U IvDC [156] In skin biopsies of sarcoidosis pts treated or
not with thalidomide.
Trimethyl
psoralen +
PUVA
Psoriasis D IvDC [157]
Biopsies of lesional skin were performed in
pts with psoriasis, before treatment, after 2
weeks of treatment or at the end of treatment.
Dehydro-
epiandro-
sterone
DE D - 1 [ 158]
Slight down-regulation. The assay was
performed on day 7. Reduction of IL-10
(opposite eﬀect respect to DEX).
Terpenes:
Calamenene
T-cadinol
Anti-
inﬂammatory,
anti-septic
UE D - 2 [ 159]
Terpenes:
Epicubenol,
Ferruginol
Anti-septic U OED [160]
MOs were cultured with G4, followed by
another 2 days with the drugs. Surprisingly
both induce IL-10 generating Treg.
Piceatannol
(stilbene
derivative)
Anti-
inﬂammatory,
immunomodu-
latory and
anti-
proliferative
UO E D [ 161]
MOs were cultured with G4 for 6 days,
followed by another 2 days in the presence of
piceatannol alone. On the contrary high
concentration of resveratrol, another stilbene
derivative, markedly reduces CD1b
expression on G4-induced iDCs (Fuggetta et
al., in preparation).
Vegetal products
Ginseng
saponins (M1
and M4)
Various U ED-2 [162] After G4 DCs were treated on day 6 only with
M1 or M4.
Vitamins
Alpha dihydroxy
vitamin D3 MS
DE D - 1 [ 163]
1,25(OH)2D3 hampers the maturation of
fully active immunostimulatory MHC-II+,
CD1a+,C D 8 0 +DCs from MOs.
D ED-1
OED [164]
CD34+ cells were collected by apheresis either
from cancer pts after chemotherapy or from
healthy donors after G-CSF treatment. For
DC generation the cells were cultured with
standard cytokines.
DE D - 2 [ 165]
DCs were obtained from MS pts. Beneﬁcial
action of vitamin D in MS may be associated
with its inhibition on both diﬀerentiation and
maturation of DCs.
DE D - 4 [ 166]
Accompanied by overexpression of miR-378
and low expression of miR-155 that could
have a role in DC function.
DE D - 1 [ 167] D3 up-regulates colony stimulating factor 1
and downregulates its receptors.
DE D - 1 [ 168] Assay was performed on day 7. Inhibition of
DC diﬀerentiation and maturation.
Calcipotriol
(vit. D3 analog)
Topical in
psoriasis DO E D [ 169] In vivo treated psoriatic skin.
aEvaluation of CD1a expression if not otherwise speciﬁed: U: upregulation; D: down-regulation; NC: no change.
bExperimental design code (see Figure 2).
cReference number.12 Clinical and Developmental Immunology
of prostaglandins and serotonin on CD1a expression in
diﬀerent experimental conditions in vitro. In all cases, the
agents show suppressive activity.
When cytokines are considered, GM-CSF and IL-4 are
not enlisted in Table 3. Actually, this cytokine combination
is used by most of in vitro tests, to induce iDCs that express
high levels of CD1 proteins (Figures 1 and 2). In particular,
GM-CSF is the most potent inducer, whereas IL-4 reinforces
the eﬀect of GM-CSF but is scarcely active if used alone.
Anumberofdatafromtheliteratureispresentlyavailable
on IFNs that show predominant inhibitory eﬀects on CD1
system. While IFNα can be involved in the transition from
iDCs to mDCs (Figure 1), IFNβ downregulates CD1 protein
expression either in vivo or in vitro. In addition this cytokine
was found to reduce the functional activity of mDCs.
Since IFNβ h a sa c q u i r e dad e ﬁ n i t er o l ei nM St r e a t m e n t ,
these results add further support to the hypothesis of the
involvement of CD1 system in MS pathogenesis.
ConsistentinhibitoryeﬀectsonCD1expressionareman-
ifested by IL-6 and IL-10 in various experimental conditions.
It must be pointed out that in many cases down-regulation
of G4-induced CD1 expression provoked by various agents
appears to be mediated by the release of IL-6 and more
frequently by the release of IL-10 that operates according to
an autocrine pattern.
Of interest, ﬁnally is the mechanism by which TGFβ
appears to maintain CD1a expression on LC generated in
vitro from puriﬁed CD34+ cells. In this case, the expression
of CD1a, that is normally found to be elevated in immature
LCs, declines with LC maturation. Since TGFβ prevents LC
maturation, it allows the long-term presence of high CD1a
levels in LCs.
6.3. Biological and Physical Agents. With the exception of
the placental growth factor, all biological and physical agents
illustrated in Table 4 provoke down-regulation of cytokine-
inducedCD1proteinexpression.Themechanismunderlying
the eﬀect of various lipids including some contained in
human serum, indicates a common target consisting in
peroxisome proliferator-activated receptor (PPAR)γ that
appears to be activated by these molecules in various exper-
imental conditions. The observation that human serum,
either for the presence of diﬀerent lipoproteins or for
the presence of IgG and β2-microglobulin (Table 4), pro-
vides inhibitory eﬀects, poses undoubtedly the question
of the eﬃciency of the CD1 system in vivo in infected
patients.
Of considerable interest is the ﬁnding that various super-
natants of human tumor cell cultures contain inhibitory
factors. Although mycoplasma contamination of cultured
cells could be, at least in part, responsible for these ﬁndings
(see Table 5), it cannot be excluded that this type of suppres-
sion of antigen-presenting function could be of relevance in
tumor-induced immune suppression.
TheinvivoimpairmentofCD1aexpressionbyultraviolet
light is not surprising, since the general immune-suppressive
eﬀects of this type of radiation has been demonstrated in
diﬀerent eﬀector functions of the immune system.
6.4. Infectious Agents or Microorganism Products. In vitro and
in vivo studies concerning modulation of CD1 system by
bacterial and chlamydial infections generally demonstrated
a CD1 upregulation (Table 5). It is reasonable to speculate
that, in certain experimental conditions, TLR-2 activation
by microorganisms could be involved [29]. Surprisingly,
however, is the ﬁnding that antral biopsies performed in H.
pilori-infected children reveal CD1a/b upregulation respect
to normal subjects, whereas in vitro exposure of MOs to
formalin-killed H. pilori prevents CD1 induction by G4.
Of particular note is the ﬁnding that CD1a is up-
regulated in vitro by G4 more vigorously in MOs obtained
from MS patients bearing an infectious disease, with respect
to MOs obtained from noninfected MS patients. This
observation has been put in relationship with the clinical
ﬁnding that subjects aﬀected by MS are at particular risk of
relapse in the course of bacterial infections. Again, this seems
to provide support to the hypothesis of a signiﬁcant role that
could be played by CD1 system in MS.
Diﬀerently from the in vivo and in vitro eﬀect of the
bacteria and chlamydia reported in Table 5, infections with
various protozoa, with at least two types of helminthes,
and viruses such as HHV-8 and Cytomegalovirus leads
to impairment of CD1 expression in various types of
experimental design. This is not surprising since the general
immunodepressive activity of these infections has been
known for several years.
When microorganism products are considered, only
attenuated Dengue-2 live vaccine, malaria-associated AMA-
1, and staphylococcus superantigen are able to up-regulate
cytokine-induced CD1 expression. Toxins and malaria
hemozoin provide opposite eﬀects on the system. A par-
ticular feature that distinguishes the activity of pertussis
toxin from the other microorganism products resides in its
unusual property of suppressing CD1a expression selectively,
without reducing the levels of the other components of
the system (i.e., CD1b and CD1c). It is not excluded that
this could allow selective analysis of CD1A gene regulation
distinct from that of the other CD1 genes.
Finally, of relevance is the ﬁnding that LPS is able to
down-regulate G4-induced CD1a. LPS, that is considered
the standard agent for generating mDCs from iDCs (Figures
1 and 2), is a common constituent of pathogenic or
nonpathogenic microorganisms, being present in the cell
wall of gram-negative bacteria. Therefore, it is reasonable to
consider that this molecule could play a signiﬁcant role in
the clinic, possibly through its modulating activity on CD1
expression and DC maturation.
7. Conclusions and Perspectives
Fine tuning of biological functions governed by a complex
signalingnetworkiscommonlyseeninlivingorganisms,and
the CD1 system does not represent an exception to this rule.
Thisopensupseveraloptionstointentionallymanipulatethe
CD1expressioninordertoenhanceordepressantigeniclipid
presentation according to the therapeutic needs. The results
of the literature analysis presented here clearly demonstrate
that a large variety of diﬀerent externally acting agents,Clinical and Developmental Immunology 13
Table 3: Eﬀect of autacoids or cytokines on CD1 molecule expression.
Molecule CD1a ED
b Ref.c Observations
Autacoids
Prostaglandin
PGE2
DE D - 4 [ 170]
DE D - 1 [ 171]
Puriﬁed CD14+ c e l l sf r o mP Bo fh e a l t h y
donors mobilized with G-CSF for allogeneic
transplantation.
DE D - 2
LD ED-3
DE D - 4
DE D - 1 [ 172]
DE D - 1 [ 173]
DE D - 1 [ 174]
Cyclopentenone
Prostaglandins
(CP) (15d-PGJ2,
12-PGJ2, PGA2,
PGD2, and PGE2)
DE D - 1 [ 175]
MOs + G4 for 7 days. CP were added during
the last 24 h of culture without adding
maturation factors. In these experimental
conditions, CP induced apoptosis.
Serotonin
(5-hydroxy-
tryptamine,
5-HT)
D
D
ED-1
ED-4 [176]
MOs. 5-HT eﬀects mediated via 5-HTR1/7.
iDCs and mDCs exposed to 5-HT for 24 h
did not show alteration of CD1a expression.
Cytokines
IFNα2a D OED [177] MOs cultured for 7 days with
(GM-CSF+IL-4+TNF-α)+ /− IFNα2a.
IFNα2b D OED [178] MOs cultured with GM-CSF +/− IFNα2b
for 5 days.
IFNα +I L - 2o r
IL-12 alone NC IvDC
OED [179]
MOs obtained from PB of pts with renal cell
cancer before, during, and after therapy
with the indicated cytokines, or from
healthy subjects were cultured with G4 for 8
days. The yield of DCs from cancer pts was
lower than that from healthy subjects.
However, the phenotype of DCs generated
from MO of pts was comparable to that of
DCs generated from MO of healthy subjects.
IFNβ1a
DE D - 2 [ 148] MOs from PB of untreated pts with MS.
DE D - 1 [ 180] M O sf r o mP Bo fu n t r e a t e do r
IFNβ1a-treated pts with MS.
DE D - 4 [ 181]
MOs from PB of untreated pts with MS.
Analysis was performed on CD1a/b/c
molecules.
DE D - 1 [ 182]
DI v D C [ 183]
E v a l u a t i o no f%o fC D 1 a +HLA-DR+ MNC
in PB of MS pts, either untreated or treated
with IFNβ1a, and in healthy subjects.
DE D - 4 [ 184] Puriﬁed CD14+ c e l l sf r o mP Bo fh e a l t h y
subjects.
IFNβ1b D ED-1 [185]
M O sf r o mP Bo fu n t r e a t e do r
IFNβ1a-treated pts with MS and from
healthy subjects.
IFNγ DE D - 1 [186,
187] M O s+G 4f o r1 2d a y s .
Il-1β NC ED-1 [188]14 Clinical and Developmental Immunology
Table 3: Continued.
Molecule CD1a ED
b Ref.c Observations
IL-3 U OED [189]
CD14+ osteoclast precursors from PB of
healthy donors cultured with (M-CSF+
RANKL) +/− IL-3 for 7 days.
IL-6
sIL-6Rα/IL-6
fusion protein
(FP6)
D
D OED [190]
GPA−CD15−CD14−CD1a−IL-6R+ myeloid
progenitors (generated after incubation of
cord blood-derived CD34+CD38− cells with
SCF+FLT3-L+TPO+IL-3 for 6-7 days) were
cultured with (SCF+FLT3-L+TPO+IL-3)
+/− IL-6 or FP6 for 11–14 days.
IL-6
sIL-6R/IL-6 fusion
protein (FP6)
D
D OED [191,
192]
CD36−CD15−CD14−CD1a−IL-6R+ myeloid
progenitors (generated after incubation of
cord blood-derived CD34+CD38− cells with
SCF+FLT3-L+TPO+IL-3 for 7 days) were
cultured with (SCF+FLT3-L+TPO+IL-3)
+/− IL-6 or FP6 for 7 days.
IL-6 DO E D [ 193]
Puriﬁed CD34+hematopoietic progenitor
c e l l sf r o mP Bo fG - C S F - t r e a t e dP t sw i t h
MM were cultured with
(FLT3-L+TNFα+GM-CSF+SCF+IL-4) +/−
IL-6 (added on day 0 or day 7 of culture) for
14 days. CD1a evaluation on day 14.
DE D - 1 [ 194] MOs. Mechanism, Il-6-induced expression
of G-CSF receptor.
IL-10
DI v E D [ 195] Psoriatic skin after systemic IL-10
administration.
DO E D [ 196] MOs cultured with (GM-CSF+IL-13) +/−
I L - 1 0f o r7d a y s .
DO E D [ 197] MOs cultured with (GM-CSF+IL-13) +/−
I L - 1 0f o r7d a y s .
IL-13 U OED [198]
MOs cultured with G4 or with
GM-CSF+IL-13 for 7 days. Higher CD1a
upregulation with GM-CSF+IL-13.
MOs cultured with G4 for 7 d and then with
IL-13 or TNFα or IL-4 for 48h. IL-13 as
aﬀective as TNFαin inducing maturation of
imDC.
Platelet factor 4 D ED-1 [199]
TGF-β1U O E D [ 200]
Puriﬁed CD34+ hematopoietic progenitor
cells from cord blood cultured with
(FLT3-L+TNFα+GM-CSF+SCF) +/− TGF-
β1 for 10–14 days. Cells generated in the
presence of TGF-β1 resemble immature LC
with high CD1a antigen expression.
Mechanism: maturation of LC leading to
CD1a down-regulation is prevented by
elevated E-cadherin expression induced by
TGF-β1.
aEvaluation of CD1a expression if not otherwise speciﬁed: D: down-regulation; U: upregulation; LD: limited down-regulation; NC: no changes.
bExperimental design code (see Figure 2).
cReference number.
either of synthetic or natural origin, can aﬀect profoundly
the expression levels of CD1 glycoproteins, with a possible
consequence on DC-mediated lipid presentation to T-cells.
Actually, Group I CD1 glycoproteins are mainly involved
in the presentation of M. tuberculosis-derived lipids to
CD1-restricted T-cells. Pharmacological ampliﬁcation of the
system could provide a signiﬁcant help for vaccination
and treatment modalities concerning millions of subjects
presently exposed to tuberculosis threat. In particular, the
rapidly expanding area of small RNAs capable of controlling
directly or indirectly the expression level of an extremely
high numbers of genes, could be carefully considered forClinical and Developmental Immunology 15
Table 4: Eﬀect of biological or physical agents on CD1 molecule expression.
Type of biological
agents Agent CD1a ED
b Ref.c Observations
Growth factors Placental growth
factor (PLGF) UE D - 2 [ 201]
Modest upregulation. PLGF antagonizes
LPS-induced down-regulation of CD1a in
iDCs.
Mechanism: inhibition of NF-kB signal
transduction pathway.
Heat-shock proteins HSP-27 D ED-1 [202,
203] Mechanism: IL-10 induction.
Immuno-complexes Anti-OVA rabbit
IgG + OVA DE D - 1 [ 204] Mechanism: interaction with FcγRI and
FcγRII.
Ligand proteins
Peptide ligand of
melanocortin-4
receptor
(NDP-MSH)
DE D - 4 [ 205] mDCs from treated precursors show
impaired ability to prime T-cells.
sLAG-3 (CD223)
soluble MHC-II
ligand
D ED-1
ED-3 [206]
CD1a down-regulation. Mechanism
(hypothesis): phosphorylation of PLCγ2,
p72syk, or AKT molecules.
Lipids
Lipids D ED-1 [207]
High individual variability of CD1a
induction after G4. Lipoproteins (VLDL >
LDL > HDL) and PPARγ activation reduce
the number of G4-induced CD1a+ cells.
Lysophosphatidic
acid (LPA) DE D - 1 [ 208] Mechanism: LPA is a potent natural ligand
for PPARγ.
Oxidized
Phospholipids DE D - 1 [ 209]
Oxidized phospholipids (generated during
inﬂammation) down-regulate CD1a/b/c and
block histone modiﬁcations required to
activate mDCs.
Malignant cell
products
Hepatoma cell
supernatant DE D - 1 [ 210]
CD1a down-regulation by hepatoma but not
normal liver cell supernatants. Induction of
Treg Mechanism: possibly IL-10-dependent.
Human renal cell
carcinoma lines DO E D [ 211]
From CD34+ progenitor cells: severe
inhibition of CD1a and APC function of
induced CDs.
Mechanism: possibly due, at least in part, to
IL-6 and macrophage colony stimulating
factor.
Leukemia cell
supernatant D ED-1 [212]
Supernatant of K562, HL-60 and DAUDI on
CD1a expression. Mechanism: at least in
part, due to IL-1β secreted by MOs in
response to leukemic cell products.
Melanoma cell
supernatant D ED-1
IvDC [213]
CD1a/b/c. Mechanism: IL-10 release
induction in vivo reduced CD1-positive cells
in metastatic melanoma.
DO E D [ 214]
LC generated in vitro from cord blood
CD34+ progenitors are CD1a-deﬁcient
when cultured with melanoma cells in a
transwell design setting.
Supernatant from
primary or
long-term
cultured tumor
cells
DE D - 1 [ 215]
Reduction of CD1a by supernatant of tumor
cell lines was much less active respect to
supernatants of primary tumors. Similar
results obtained with CD34+
progenitor-derived DCs. Mechanism: at least
in part mediated by PGE2 released by
primary tumor cells.16 Clinical and Developmental Immunology
Table 4: Continued.
Type of biological
agents Agent CD1a ED
b Ref.c Observations
Nucleotides cAMP, cGMP D ED-1 [216]
cAMP increase was mimicked by the
adenylate cyclase activator forskolin or
cAMP analog 8 bromo-cAMP; cGMP
increase was mimicked by 8 bromo-cGMP;
increase of both was induced by PDE
inhibitor IBMX. Down regolation of CD1a
is followed by impairment of LPS-induced
mDC function.
Serum and serum
components
Human serum D ED-1
[217]
Human serum lipids: impairment of
CD1a/b/c transcription. Reduced induction
of CD1c-restricted T-cell responses.
Mechanism: PPARγ activation.
[218] Human serum: Mechanism: PPARγ
activation and IL-10 induction.
[219] Autologous serum (iDCs from MOs or from
CD34+ precursors).
IgG D ED-1 [220]
Down-regulation of CD1a/b/c and
upregulation of CD-1d transcripts.
Mechanism: IgG-mediated activation of Fcγ
receptor FcγRIIa (CD32a).
D ED-1
ED-4 [221]
This study starts from the observation that
intravenous immunoglobulin attenuates
MS.
β2-microblobulin D ED-1
ED-4 [222]
Down-regulation of CD1a and mDC
function. Mechanism: inhibition of MAPK,
ERK, MEK, and NF-kB, and activation of
STAT3.
Physical agents
Ultraviolet light
UVAI
(340–400nm) DI v D C [ 223] Decrease of CD1a+ LC in a epidermis 3 days
after ultraviolet exposure.
UVB
DI v D C [ 224]
UV irradiation induces CD1a+ LC
down-regulation and IL-10 induction in
vivo in skin. This is prevented in vivo by
Zn-containing or octylmetoxy cinnamate
sunscreen preparations.
DI v D C [ 225]
CD1a+ Langerhans cell loss after exposure of
human epidermis and dermis to UVB,
accompanied by inﬁltration with IL-10
producing macrophages.
DI v D C [ 226]
Organ culture in vitro of human cornea
(immunohistochemistry): low-dose UVB
(100mJ/cm2) decreases HLA-DR and CD1a
expression of organ-cultured human
corneas and induces moderate corneal
injuries, and might be useful for preventing
allograft rejection.
aEvaluation of CD1a expression if not otherwise speciﬁed: U: upregulation; D: down-regulation.
bExperimental design code (see Figure 2).
cReference number.Clinical and Developmental Immunology 17
Table 5: Inﬂuence exerted by infectious agents or microorganism products on group 1 CD1 antigen expression.
Infectious
Agent Agent CD1a ED
b Ref.c Observations
Bacteria
Helicobacter pilori
E. coli DE D - 1 [ 227] In vitro exposure to paraformaldehyde-ﬁxed
bacteria. IL-10 independent.
Helicobacter pilori
(in vivo) UI v D C [ 228]
In vivo detected by antral biopsies (lamina
propria): increased CD1a and CD1b in
infected children with respect to normal
subjects. Expression of local immune
responses.
Propionibacterium
acnes UE D - 2 [ 229] Heat-killed bacteria added on day 6 to iDCs
of pts with acne vulgaris.
Various U OED [230]
Increased CD1a expression in in vitro
generation of mDCs from MS pts with
bacterial infections versus MS pts without
infections.
Chlamydia Chlamydia
trachomatis UI v D C [ 231]
Myeloid DCs collected from cervical mucosa
of chlamydia-infected woman show myeloid
DCs with increased CD1a expression with
r e s p e c tt ot h a to fh e a l t h yw o m e n .
Mycoplasma
Mycoplasma
present in cell
culture
supernatant
DE D - 1 [ 232]
If mycoplasma is removed, culture
supernatants are no more able to
down-regulate CD1a.
Protozoa
Leishmania
donovani DE D - 1 [ 233]
L. donovani infection in vitro impairs
induction of CD1a/b/c expression in terms
of gene transcript and protein.
Leishmania
amazonensis D ED-1
ED-4 [234]
Leishmania or soluble Leishmania antigen
inhibited CD1a expression, but did not
prevent further DC maturation toward
CD83+ mDCs.
Leishmania
donovani and
Leishmania major
DO E D [ 235]
In vitro G4-induced iDCs were infected with
L. donovani or L. major on day 7 and tested
for CD1a/b/c/d expression 8 h later.
Down-regulation of mainly Group I CD1
molecules at the transcriptional (qRT-PCR)
and surface expression levels was detected.
Toxoplasma
gondii NC OED [236] In vitro infection of untreated MOs with T.
gondii does not induce CD1a.
Helminthes
Necator
Americanus DO E D [ 237]
In vitro G4-induced CD1a in mDCs is lower
when MOs were obtained from infected pts
versus normal donors.
Echinococcus
granulosus D ED-1
ED-4
[238,
239]
Hydatid cyst components (AgB- and SHF)
down-regulate CD1a and further prevent
IL-12 production, increasing IL-10 release.
Viruses (for
HIV& HTLV-I
see text)
Human Herpes
Virus-8 (alive or
UV-inactivated)
DE D - 1 [ 240]
Reduced mDC activity and sixfold reduction
in IL-12 (p70) production with consequent
impairment of T-cell-mediated responses.
Cytomegalovirus D ED-1 [241]
CD1a assay at day 7, before adding LPS (to
evaluate iDC CD1a expression).
Down-regulation of CD1a occurs also with
UV-inactivated virus. Moreover,
HCMV-infected mDCs were unable to
induce a T-cell response, in line with the
immunodepressive eﬀects of HCMV
infection.18 Clinical and Developmental Immunology
Table 5: Continued.
Infectious
Agent Agent CD1a ED
b Ref.c Observations
Micro-
Organism
products
Bordetella
pertussis Pertussis toxin D ED-1 [242]
Selective suppression of CD1a (mRNA and
protein) but not of CD1b and CD1c.
LPS-induced mDCs are functionally
normal.
Candida
albicans Supernatant D ED-1 [243]
C. albicans supernatants contain a
glycoprotein termed “Secretory IL-12
Inhibitory Factor”, able to down-regulate
CD1a expression and IL-12 production by
iDCs and DCs.
Dengue
Dengue-2 (live
attenuated
vaccines)
UE D - 2 [ 244]
DC maturation step 2 was attained with live
attenuate vaccine LAV2 or DEN2 without
adding LPS. Heat-inactivated virus was used
as a negative control for virus infection.
CD1a assay was performed after incubation
at 32◦Cf o r4 8h .
Malaria
Hemozoin
(malaria
pigment)
D ED-1
ED-4 [245]
Mechanism: increased PPARγ expression
(qRT-PCR) following hemozoin-induced
activation in MOs.
Atypical
Membrane
Antigen-1
(AMA-1)
UE D - 4 [ 246]
mDCs of P. vivax infected pts show lower
CD1a expression than that of mDCs
developed in vitro from MOs of noninfected
controls. In vitro exposure to AMA-1
increases CD1a levels in mDCs developed in
vitro from MOs of infected donors.
Mycotoxins T-2 toxin D ED-1 [247] Strong inhibition.
Staphylococcus
aureus
Staphylococcus
superantigen UI v D C [ 248]
CD1a+ cell number in the epidermis was
signiﬁcantly higher in the lesional skin with
respect to that in non-lesional skin from
atopic dermatitis pts or to that in the skin
from normal donors.
Various
bacteria LPS D ED-1 [249]
LPS (from Salmonella)w a sa d d e dt o
MOs+G4 culture on day 0 instead of on day
5–9, as usually used for inducing iDC
maturation to mDCs. Mechanism: in part by
induction of IL-10, and mostly by
MAPKp38 activation followed by ERK and
NF-kB inactivation.
aEvaluation of CD1a expression if not otherwise speciﬁed: U: upregulation; D: down-regulation.
bExperimental design code (see Figure 2).
cReference number.
planning new types of antimycobacterial vaccines. It is
reasonable to predict that properly designed siRNA(s) could
becombinedinanearfuture,withBCGorBCG-likevaccines
in order to obtain gene silencing vaccines able to inactivate
the intracellular signals responsible of Group I CD1 protein
suppression.
Abbreviations
Ac2SGL: Acylated sulfoglycolipid
APC: Antigen-presenting cells
ASA: Acetylsalicylic acid
ATF-2: Activating transcription factorClinical and Developmental Immunology 19
ATRA: All trans-retinoic acid
AZT: Zidovudine
BCG: Bacillus Calmette-Guerin
BDP: Beclomethasone dipropionate
CRE: cAMP response element
CREB-1: CRE-binding protein
DC: Dendritic cells
DEX: Dexamethasone
ERK: Extracellular signal-regulated kinases
G4: GM-CSF + IL-4
GA: Glatiramer acetate
GM-CSF: Granulocyte-macrophage colony
stimulating factor
GST: Gold sodium thiomalate
HDAC: Histone deacetylases
iDC: Immature dendritic cells
IFN: Interferon
IL: Interleukin
LC: Langerhans cells
LPS: Lipopolysaccharides
MAPK: Mitogen-activated protein kinase
mDC: Mature dendritic cells
MDR: Multidrug resistance
MIN: Minocycline
MM: Multiple myeloma
MMF: Monomethyl-fumarate
MOs: Monocytes
MRP1: Multidrug resistance protein 1
MS: Multiple sclerosis
MTP: Microsomal triglyceride transfer
protein
NFA: Niﬂumic acid
NSAID: Nonsteroidal anti-inﬂammatory
drugs
PBMN: Peripheral blood mononuclear cells
PPAR: Peroxisome proliferator-activated
receptor
pts: Patients
RA: Rheumatoid arthritis
TCR: T-cell receptor
TLR: Toll-like receptors
TNF: Tumor necrosis factor.
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